The DOI matches its Crossref record.
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
Open accessAbstract
Background & aims Long-term ursodeoxycholic acid (UDCA) therapy slows the progression of primary biliary cirrhosis. This study examined the effect of UDCA therapy on survival free of liver transplantation in a large group of patients.Methods Data from three clinical trials were combined in which patients with primary biliary cirrhosis were randomly assigned to receive UDCA (n = 273) or placebo (n = 275). After 2 years, patients from French and Canadian studies received UDCA for up to 2 years. Patients from the American study remained on their assigned treatment for up to 4 years.Results Survival free of liver transplantation was significantly improved in the patients treated with UDCA compared with the patients originally assigned to placebo (P < 0.001; relative risk, 1.9; 95% confidence interval, 1.3-2.8). Subgroup analyses showed that survival free of liver transplantation was significantly improved in medium- and high-risk groups (serum bilirubin level, 1.4 to 3.5 or > 3.5 mg/dL; P < 0.0001 and P < 0.03, respectively) and histological stage IV subgroup (P < 0.01).Conclusions Long-term UDCA therapy improves survival free of liver transplantation in patients with moderate or severe disease. An effect in patients with mild disease is probably not found because they do not progress to end-stage disease in 4 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some studies with extended follow-up have also shown improved survival.(59,62,63)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, patients with earlier histologic stage usually respond more favorably to UDCA than patients with advanced disease, although patients with advanced disease may benefit in survival or avoid liver transplantation with this therapy.(63)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with ursodeoxycholic acid decreases the levels of the biochemical markers of cholestasis and extends the time to liver transplantation.4,5”
From A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Still being checked.
Research works printed but not linked: 7
- [2]2. Babbs C, Hunt LP, Haoubi NY, Smith A, Rowan BP, Warnes TW. sponse to ursodeoxycholic acid. Gut 1995;36:935-938. Type III procollagen peptide: a marker of disease activity and 15. Christensen E, Crowe JP, Doniach D, Popper H, Ranek L, Rode ´s prognosis in primary biliary cirrhosis. Lancet 1988;1:1021- J, Tygstrup N, Williams R. Clinical pattern and course of disease 1024. in primary biliary cirrhosis based on an analysis of 236 patients.
- [3]3. Poupon RE, Balkau B, Gue ´chot J, Heintzmann F. Predictive fac- Gastroenterology 1980;78:236-246. tors in ursodeoxycholic acid-treated patients: role of serum mark- 16.
- [4]4. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival ers of connective tissue. Hepatology 1994;19:635-640. of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994;20:701-713.
- [5]5. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic Received June 20, 1996. Accepted March 14, 1997. factor in primary biliary cirrhosis. Gut 1979;20:137-140. Address requests for reprints to: Rene ´e E. Poupon, Dr. Sci., IN- 18.
- [6]6. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance SERM Unite ´21, 16, Avenue Paul-Vaillant-Couturier, 94807 Villejuif of clinical and histological features in asymptomatic and symp- Cedex, France. Fax: (33) 01-4726-9454. tomatic primary biliary cirrhosis. N Engl J Med 1983;308:1-7. The authors thank Anne-Marie Bonnand for her helpful discussion
- [7]7. Christensen E, Neuberger J, Crowe JP, Altman DG, Popper H, and Christine Gue ´mene ´for her expert technical assistance. Portmann B, Doniach D, Ranek L, Tygstrup N, Williams R. Benefi- Presented, in part, at the 43rd Annual Meeting of the American cial effect of azathioprine and prediction of prognosis in primary Society for the Study of Liver Diseases, May 14-17, 1995, San biliary cirrhosis: final results of an international trial. Gastroenter- ology 1985;89:1084-1091.
- [8]8. Brunner of Brunner's Glands Johann Conrad Brunner (1653-1727) was born at Schaffhausen, Switzer- land, near the Rheinfall. He graduated from the university at Strasbourg, and later studied in Paris and then in England under Thomas Willis. He became a professor of anatomy at Heidelberg where he published his Disser- tatio inauguralis de glandulis duodeno intestino in 1687. Actually, Brunner's father-in-law J. J. Wepfer had previously described the glands of the duode- nal mucosa in 1679, but it was Brunner's inaugural dissertation that at- tracted attention, and hence the eponym. / 5E20$$0021 08-08-97 18:15:00 gasas WBS-Gastro
Cited by
Sorted by citations
Items 101–200 of 647
Gong, Y., Huang, Z., Christensen, E., & Gluud, C. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01235.x · Cited by 131
Bezafibrate treatment: a new medical approach for PBC patients?
Kanda, T., Yokosuka, O., Imazeki, F., & Saisho, H. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-002-1102-7 · Cited by 129
Talwalkar, J. A., Keach, J. C., Angulo, P., & Lindor, K. D. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05703.x · Cited by 127
Self-citationPathogenesis and Treatment of Pruritus in Cholestasis
Kremer, A. E., Beuers, U. H., Elferink, R. P. J. O., & Pusl, T. (2008) · Drugs · doi:10.2165/00003495-200868150-00006 · Cited by 128
Wunsch, E., Trottier, J., Milkiewicz, M., Raszeja‐Wyszomirska, J., Hirschfield, G. M., Barbier, O., & Milkiewicz, P. (2014) · Hepatology · doi:10.1002/hep.27074 · Cited by 129
Nakamura, M., Shimizu‐Yoshida, Y., Takii, Y., Komori, A., Yokoyama, T., Ueki, T., Daikoku, M., Yano, K., Matsumoto, T., Migita, K., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.016 · Cited by 126
Ursodeoxycholic acid — adverse effects and drug interactions
Hempfling, W., Dilger, K., & Beuers, U. H. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01792.x · Cited by 127
Shi, J. Q., Wu, C., Lin, Y., Chen, Y.-X., Zhu, L., & Xie, W.-F. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00634.x · Cited by 124
Myers, R. P., Swain, M. G., Lee, S. S., Shaheen, A. A., & Burak, K. W. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.51 · Cited by 124
Glantz, A., Reilly, S., Benthin, L., Lammert, F., Mattsson, L., & Marschall, H. (2007) · Hepatology · doi:10.1002/hep.21987 · Cited by 123
Ursodeoxycholic acid: Mechanism of action and novel clinical applications
Ikegami, T., & Matsuzaki, Y. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00297.x · Cited by 124
Fat-soluble vitamin levels in patients with primary biliary cirrhosis
Phillips, J. R., Angulo, P., Petterson, T., & Lindor, K. D. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.04134.x · Cited by 118
Self-citationPrimary biliary cirrhosis: Pathophysiology, clinical presentation and therapy
Purohit, T. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i7.926 · Cited by 121
Ursodeoxycholic Acid for the Treatment of Primary Biliary Cirrhosis
Lindor, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmct074694 · Cited by 115
Self-citationBosch, A., Dumortier, J., Maucort-Boulch, D., Scoazec, J.-Y., Wendum, D., Conti, F., Morard, I., Rubbia-Brandt, L., Terris, B., Radenne, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.038 · Cited by 114
Self-citationGuidelines for the management of primary biliary cirrhosis
Cirrhosis, W. S. (. V. F. C. P. G. F. P. B. (2014) · Hepatology Research · doi:10.1111/hepr.12270 · Cited by 111
Functional and Structural Features of Cholangiocytes in Health and Disease
Maroni, L., Haibo, B., Ray, D., Zhou, T., Wan, Y., Meng, F., Marzioni, M., & Alpini, G. D. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.05.005 · Cited by 116
Truth Survival in Clinical Research: An Evidence-Based Requiem?
Poynard, T., Munteanu, M., Ratziu, V., Benhamou, Y., Martino, V. D., Taı̈eb, J., & Opolon, P. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-12-200206180-00010 · Cited by 107
Sakisaka, S., Kawaguchi, T., Taniguchi, E., Hanada, S., Sasatomi, K., Koga, H., Harada, M., Kimura, R., Sata, M., Sawada, N., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.25086 · Cited by 106
Extrahepatic Manifestations of Primary Biliary Cholangitis
Chalifoux, S. L., Konyn, P., Choi, G., & Saab, S. (2017) · Gut and Liver · doi:10.5009/gnl16365 · Cited by 105
Carithers, R. L. (2000) · Liver Transplantation · doi:10.1002/lt.500060122 · Cited by 104
Hendrickse, M. T., Rigney, E., Giaffer, M. H., Soomro, I. N., Triger, D. R., Underwood, J. C. E., & Gleeson, D. C. (1999) · Gastroenterology · doi:10.1053/gast.1999.0029900400 · Cited by 101
Mayo, M. J., Pockros, P. J., Jones, D. E., Bowlus, C. L., Levy, C., Patanwala, I., Bacon, B. R., Luketic, V. A., Vuppalanchi, R., MEDENDORP, S. V., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1305 · Cited by 100
Cabrera, D., Arab, J. P., & Arrese, M. A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_241 · Cited by 104
Ursodeoxycholic Acid and Long-Term Survival in Primary Biliary Cirrhosis
Levy, C., & Angulo, P. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04094.x · Cited by 99
Harms, M. H., Lammers, W. J., Thorburn, D., Corpechot, C., Invernizzi, P., Janssen, H. L. A., Battezzati, P. M., Nevens, F., Lindor, K. D., Floreani, A., et al. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.440 · Cited by 98
Self-citationCorpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000529 · Cited by 94
Ursodeoxycholic acid therapy in hepatobiliary disease
Kowdley, K. V. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00318-1 · Cited by 95
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis
Corpechot, C., Chazouillères, O., Belnou, P., Montaño‐Loza, A. J., Mason, A. L., Ebadi, M., Eurich, D., Chopra, S., Jacob, D., Schramm, C., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.043 · Cited by 91
Self-citationNatural history of primary biliary cirrhosis
Parés, A., & Rodés, J. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00100-4 · Cited by 89
Samur, S., Klebanoff, M., Banken, R., Pratt, D. S., Chapman, R., Ollendorf, D. A., Loos, A. M., Corey, K., Hur, C., & Chhatwal, J. (2017) · Hepatology · doi:10.1002/hep.28932 · Cited by 89
Kriegermeier, A. A., & Green, R. R. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00149 · Cited by 91
Murillo Perez, C. F., Goet, J. C., Lammers, W. J., Gulamhusein, A., van Buuren, H. R., Ponsioen, C. Y., Carbone, M., Mason, A., Corpechot, C., Invernizzi, P., et al. (2018) · Hepatology · doi:10.1002/hep.29717 · Cited by 88
Self-citationAngulo, P., Patel, T. C., Jorgensen, R. A., Therneau, T. M., & Lindor, K. D. (2000) · Hepatology · doi:10.1053/jhep.2000.18663 · Cited by 90
Self-citationSilveira, M. G., Brunt, E. M., Heathcote, J., Gores, G. J., Lindor, K. D., & Mayo, M. J. (2010) · Hepatology · doi:10.1002/hep.23637 · Cited by 87
Self-citationRecurrent Primary Biliary Cirrhosis
Guy, J. E., Qian, P., Lowell, J. A., & Peters, M. G. (2005) · Liver Transplantation · doi:10.1002/lt.20511 · Cited by 87
Use of ursodeoxycholic acid in liver diseases
Kumar, D., & Tandon, R. K. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02376.x · Cited by 88
S2k Leitlinie Autoimmune Lebererkrankungen
Authors, Collaborators:, durch:, E. B., Deutsche Gesellschaft für Gastroenterologie, V. U. S. (. (., (DGIM), D. G. F. I. M., (DCCV), D. M. C. U. V., e.V., D. L., (DEGUM), D. G. F. U. I. D. M., (DGE-BV), D. G. F. E. U. B. V., (DGKJ), D. G. F. K. U. J., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-120199 · Cited by 87
Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis
Reshetnyak, V. I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i25.7683 · Cited by 86
Bonnand, A.-M., Heathcote, J., Lindor, K. D., & Poupon, R. E. (1999) · Hepatology · doi:10.1002/hep.510290140 · Cited by 85
Self-citationHuet, P., Vincent, C., Deslaurier, J., Coté, J., Matsutami, S., Boileau, R., & Huet–van Kerckvoorde, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.019 · Cited by 84
Pharmacology of bile acids and their derivatives: Absorption promoters and therapeutic agents
Mikov, M., Fawcett, J. P., Kuhajda, K., & Kevrešan, S. (2006) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190714 · Cited by 89
Cheung, A., Lammers, W. J., Perez, C. F. M., van Buuren, H. R., Gulamhusein, A. F., Trivedi, P. J., Lazaridis, K. N., Ponsioen, C. Y., Floreani, A., Hirschfield, G. M., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.12.028 · Cited by 84
Self-citationEffect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis
Rost, D., Rudolph, G., Kloeters-Plachky, P., & Stiehl, A. (2004) · Hepatology · doi:10.1002/hep.20370 · Cited by 84
Ursodeoxycholic acid for primary biliary cirrhosis
Gluud, C. N., & Christensen, E. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551 · Cited by 85
Use of ursodeoxycholic acid in patients with liver disease
Angulo, P. (2002) · Current Gastroenterology Reports · doi:10.1007/s11894-002-0036-9 · Cited by 84
Pathogenesis and Management of Pruritus in PBC and PSC
Kremer, A. E., Namer, B., Bolier, R., Fischer, M. J. M., Elferink, R. P. J. O., & Beuers, U. H. (2015) · Digestive Diseases · doi:10.1159/000440829 · Cited by 84
Stimulation of ATP secretion in the liver by therapeutic bile acids
Nathanson, M. H., Burgstahler, A. D., Masyuk, A. I., & LaRusso, N. F. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3580001 · Cited by 82
Leuschner, M., Dietrich, C. F., You, T., Seidl, C., Raedle, J., Herrmann, G., Ackermann, H., & Leuschner, U. (2000) · Gut · doi:10.1136/gut.46.1.121 · Cited by 81
Heurgué, A., Vitry, F., Diebold, M.-D., Yaziji, N., Bernard-Chabert, B., Pennaforte, J.-L., Picot, R., Louvet, H., Frémond, L., Geoffroy, P., et al. (2007) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(07)89323-7 · Cited by 80
Rivard, A. L., Steer, C. J., Kren, B. T., Rodrigues, C. M. P., Castro, R. E., Bianco, R. W., & Low, W. C. (2007) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x07004813 · Cited by 80
Ursodeoxycholic acid for primary biliary cirrhosis
Gong, Y., Huang, Z. B., Christensen, E., & Gluud, C. N. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551.pub2 · Cited by 81
Dyson, J. K., Wilkinson, N., Jopson, L., Mells, G., Bathgate, A., Heneghan, M. A., Neuberger, J., Hirschfield, G. M., Ducker, S. J., The UK‐PBC Consortium, et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13794 · Cited by 78
Badman, M. K., Chen, J., Desai, S., Vaidya, S. S., Neelakantham, S., Zhang, J., Gan, L., Danis, K., Laffitte, B. A., & Klickstein, L. B. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.762 · Cited by 78
Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis
Momah, N., Silveira, M. G., Jorgensen, R., Sinakos, E., & Lindor, K. D. (2012) · Liver International · doi:10.1111/j.1478-3231.2011.02678.x · Cited by 77
Self-citationPPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
Colapietro, F., Gershwin, M. E., & Lleò, A. (2023) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2023.100188 · Cited by 81
Ursodeoxycholic acid treatment of vanishing bile duct syndromes
Pusl, T. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i22.3487 · Cited by 77
Diagnosis and Management of Cholestatic Liver Disease
Heathcote, E. J. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.05.008 · Cited by 75
Self-citationInvernizzi, P., Setchell, K. D. R., Crosignani, A., Battezzati, P. M., Larghi, A., O’Connell, N. C., & Podda, M. (1999) · Hepatology · doi:10.1002/hep.510290220 · Cited by 74
Novel and emerging therapies for cholestatic liver diseases
Goldstein, J., & Levy, C. (2018) · Liver International · doi:10.1111/liv.13880 · Cited by 74
Review article: current management of primary sclerosing cholangitis
Cullen, S., & Chapman, R. W. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02407.x · Cited by 74
Kowdley, K. V., Hirschfield, G. M., Coombs, C., Malecha, E. S., Bessonova, L., Li, J., Rathnayaka, N. S., Mells, G. F., Jones, D. E., Trivedi, P. J., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003029 · Cited by 73
Kim, M. Y., Cho, M.-Y., Baik, S. K., Jeong, P. H., Suk, K. T., Jang, Y. O., Yea, C. J., Kim, J. W., Kim, H. S., Kwon, S. O., et al. (2012) · Liver International · doi:10.1111/j.1478-3231.2012.02774.x · Cited by 71
Nousia‐Arvanitakis, S., Fotoulaki, M., Economou, H., Xefteri, M., & Galli‐Τsinopoulou, A. (2001) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200104000-00009 · Cited by 71
Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis
Yamazaki, K., Suzuki, K., Nakamura, A., Sato, S., Lindor, K. D., Batts, K. P., Tarara, J. E., Kephart, G. M., Kita, H., & Gleich, G. J. (1999) · Hepatology · doi:10.1002/hep.510300121 · Cited by 70
Self-citationThe therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent
Rodrigues, C. M., & Steer, C. J. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.7.1243 · Cited by 70
Barclay, A. R., Beattie, L. M., Weaver, L. T., & Wilson, D. C. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04514.x · Cited by 67
Rust, Sauter, Oswald, Büttner, Kullak‐Ublick, Paumgartner, & Beuers (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00606.x · Cited by 64
Omata, M., Yoshida, H., Toyota, J., Tomita, E., Nishiguchi, S., Hayashi, N., Iino, S., Makino, I., Okita, K., Toda, G., et al. (2007) · Gut · doi:10.1136/gut.2007.120956 · Cited by 64
Hazzan, R., & Tur‐Kaspa, R. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c115b3 · Cited by 63
Clinical Epidemiology of Primary Biliary Cirrhosis
Lazaridis, K. N., & Talwalkar, J. A. (2007) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000225653.07932.8f · Cited by 64
Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets
Paumgartner, G. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i28.4445 · Cited by 63
Wimmer, R., Hohenester, S. D., Pusl, T., Denk, G., Rust, C., & Beuers, U. H. (2008) · Gut · doi:10.1136/gut.2007.140871 · Cited by 64
FXR: a target for cholestatic syndromes?
Cai, S., & Boyer, J. L. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.3.409 · Cited by 62
Chen, X., Xu, J., Zhang, C., Yu, T., Wang, H., Zhao, M., Duan, Z.-H., Zhang, Y., Xu, J.-M., & Xu, D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.03.007 · Cited by 60
Hilscher, M. B., Kamath, P. S., & Eaton, J. E. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.01.015 · Cited by 59
Levitsky, J., Hart, J. A. L., Cohen, S. M., & Te, H. S. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50132 · Cited by 58
Development of autoimmune hepatitis in primary biliary cirrhosis
Gossard, A. A., & Lindor, K. D. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01538.x · Cited by 57
Self-citationPredicting outcome in primary biliary cirrhosis
Lammers, W. J., Kowdley, K. V., & van Buuren, H. R. (2014) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30838-5 · Cited by 56
Harms, M. H., Janssen, Q. P., Adam, R. A., Duvoux, C., Mirza, D. F., Hidalgo, E. L., Watson, C. J. E., Wigmore, S. J., Pinzani, M., Isoniemi, H., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15060 · Cited by 55
Papatheodoridis, G., Hadziyannis, E. S., Deutsch, M. J., & Hadziyannis, S. J. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05923.x · Cited by 56
Pharmacological interventions for primary biliary cholangitis
Saffioti, F., Gurusamy, K. S., Eusebi, L. H., Tsochatzis, E. A., Davidson, B. R., & Thorburn, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011648.pub2 · Cited by 54
Boone, R. H., Cheung, A. M., Girlan, L. M., & Heathcote, E. J. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-8015-x · Cited by 54
Self-citationUrsodeoxycholic acid for primary biliary cirrhosis: lessons from the pastissues for the future
Poupon, R. E. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80232-9 · Cited by 54
Self-citationAlmasio, P. L., Floreani, A., Chiaramonte, M., Provenzano, G., Battezzati, P. M., Crosignani, A., Podda, M., Todros, L., Rosina, F., Saccoccio, G., et al. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00869.x · Cited by 53
Cost–Effectiveness of Ursodeoxycholic Acid Therapy in Primary Biliary Cirrhosis
Pasha, T. M., Heathcote, J., Gabriel, S. E., Cauch‐Dudek, K., Jorgensen, R. A., Therneau, T. M., Dickson, R. E., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290116 · Cited by 53
Self-citation‘Out‐patient’ albumin dialysis for cholestatic patients with intractable pruritus
Leckie, P., Tritto, G., Mookerjee, R., Davies, N., Jones, D., & Jalan, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.04994.x · Cited by 51
Haber, B. A., & Russo, P. (2003) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(03)00049-9 · Cited by 52
Varices in early histological stage primary biliary cirrhosis
Ali, A. H., Sinakos, E., Silveira, M. G., Jorgensen, R. A., Angulo, P., & Lindor, K. D. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181f18c4e · Cited by 50
Self-citationObeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 50
Self-citationObeticholic acid for the treatment of primary biliary cholangitis
Ali, A. H., & Lindor, K. D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1218471 · Cited by 50
Self-citationNakano, T. (2002) · Hepatology Research · doi:10.1016/s1386-6346(01)00148-6 · Cited by 49
Bonis, P. A., & Kaplan, M. M. (1999) · Gastroenterology · doi:10.1053/gast.1999.0029900395 · Cited by 49
Corpechot, C., Poujol‐Robert, A., Wendum, D., Galotte, M., Chrétien, Y., Poupon, R. E., & Poupon, R. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0918.x · Cited by 48
Self-citationBellentani, S. (2005) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200502000-00001 · Cited by 47
Lanzini, A., Tavonatti, M. D., Panarotto, B., Scalia, S., Mora, A., Benini, F., Baisini, O., & Lanzarotto, F. (2003) · Gut · doi:10.1136/gut.52.9.1371 · Cited by 47
Combes, B., Luketic, V. A., Peters, M. G., Zetterman, R. K., García–Tsao, G., Muñoz, S. J., Lin, D.-Y., Flye, N. L., & Carithers, R. L. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04047.x · Cited by 47
Ljubuncic, P., Tanne, Z., & Bomzon, A. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005615306596 · Cited by 47
Turcios, N. L. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000155140.63510.cd · Cited by 46
Nguyen, D. L., Juran, B. D., & Lazaridis, K. N. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2010.07.006 · Cited by 46
Metadata
- Authors
- Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E.
- Affiliations
- Mayo Clinic (US)
- Inserm (FR)
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 1997-09
- Volume
- 113
- Issue
- 3
- Pages
- 884-890
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2071394537
- Semantic Scholar
- b05e12d331fd48ec432f894f09036aaff9a53c62
- Cited by
- 648
- References
- 0
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 15 · 2023: 9 · 2022: 5 · 2021: 15 · 2020: 21 · 2019: 23 · 2018: 27 · 2017: 26 · 2016: 12 · 2015: 24 · 2014: 26 · 2013: 13 · 2012: 17
- FWCI
- 21.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- ursodeoxycholic acid, primary biliary cirrhosis, liver transplantation, disease severity, serum bilirubin, subgroup analysis, treatment efficacy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cause of Death, Female, Forecasting, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Postoperative Care, Severity of Illness Index, Ursodeoxycholic Acid, Survival Analysis, Liver Transplantation, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
